Short answer
Bio-Techne (TECH) filed its Q4 2025 10-Q quarterly report on Feb 4, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $296M (down 0.4% year over year) with net income of $38M.
Q4 2025 key financials · XBRL
- Revenue
- $296M
- −0.4% YoY · +3.3% QoQ
- Net income
- $38M
- +8.9% YoY · −0.5% QoQ
- Operating margin
- 18.4%
- Gross margin
- 64.6%
- EPS (diluted)
- $0.25
- +19.0% YoY · +4.2% QoQ
Source: XBRL data from the Bio-Techne (TECH) Q4 2025 10-Q on SEC EDGAR. USD.
Bio-Techne Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $295.9M flat YoY for Q2 FY25; six months $582.4M, down 1% YoY; organic revenue flat in quarter, slight FX and held-for-sale impacts
- Operating margin Protein Sciences 39.3% vs 41.2% YoY Q2; Diagnostics 10.4% vs 3.9% YoY Q2, drove margin improvement overall
- Protein Sciences segment sales $215.1M up 2% YoY Q2; Diagnostics and Spatial Biology sales $81.2M down 4% YoY Q2 with 3% organic growth
- Cash and equivalents $172.9M as of Dec 31, 2025 up from $162.2M June 30, 2025; operating cash flow $110M six months down from $148.2M prior year
- Management expects tax rate 25%-29% FY26; forecasts $18M capex; notes potential $1B Wilson Wolf acquisition payment fiscal 26-28 as upcoming cash outflow
Risk Factors
- Continued supply chain disruptions risk impacting production schedules carried from 10-K
- Dependence on third-party suppliers with potential for raw material shortages carried from 10-K
- Competition from larger, established life science tools companies remains market threat carried from 10-K
- Currency fluctuations, particularly EUR and GBP exposure, may affect reported revenues carried from 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bio-Techne quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.